Biotech hails trial results for antidepressant paired with genetic test
Anonymous
No. 83900 [Open] [Reply]
Actions 
Hans Eriksson, chief medical officer of Munich-based HMNC Brain Health, called the study of its BH-200 drug in 338 patients with serious depression “a major step forward in precision psychiatry”.

https://www.ft.com/content/4b5f120f-5000-4671-a7a0-5eceedb12da5?utm_source=chatgpt.com